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SIRS, In parallel to their use for Crohn's disease (CD), anti-tumour   necrosis   factor   (TNF)   therapies   have 
become a powerful approach for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing 
spondylarthropathy (SpA) and data are becoming available concerning the effects of anti-TNF on bone 
remodelling. Our paper clearly indicates that infliximab treatment is associated with an improvement of bone 
formation as measured by three different markers of bone formation in CD1. Similar results were obtained by 
Ryan et al2. We agree with Kunisaki et al. that the effect on bone formation might be critical and possibly 
predominant in CD. Indeed, TNF is a cytokine known to inhibit bone formation and the use of anti-TNF therapy 
might be associated with a direct positive effect on bone remodelling in CD. Another possibility suggested by 
Kunisaki et al. is that the intestinal healing would be associated with an improvement in the absorption of 
calcium and vitamin D which would result in a better mineralization of bone matrix and an improvement of bone 
quality. While we agree with this possibility, particularly as a rapid mucosal healing has also been described in 
CD after infliximab, we favour the hypothesis that an improvement of inflammation and the immune reaction in 
the intestine is associated with a decrease in local and serum mediators that influence bone remodelling, even if 
there was no significant correlation in our series between evolution of bone markers and systemic inflammatory 
markers such as C-reactive protein (CRP). Of interest, serum from children with newly diagnosed inflammatory 
bowel disease (IBD) who had not received corticosteroid for 1 year reduced osteoblast differentiation and nodule 
formation, underlying the importance of inflammatory mediators on bone formation.3 
In our study, we also showed a relevant decrease in serum C-telopeptide of type I collagen (CTX), a marker of 
bone resorption after infliximab treatment. While levels of serum N-telopeptide cross-linked type I collagen 
(NTX). Another marker of bone resorption, were found to be slightly decreased in the study by Ryan et al.2, 
changes did not reach statistical significance. Kunisaki et al. did not find any change in bone resorption and 
suggest that the improvement in bone mineral density (BMD) might be mostly explained by the effect on bone 
formation. Results concerning CTX and NTX have to be analysed with prudence as small populations of patients 
are used and the variability estimates, for example, for NTX measurement might reach 10%.4  Moreover, 
difference might be influenced by the methodology itself. Ideally, standardization of the timing and collection of 
samples in fasting patients should be performed to avoid variability because of circadian rhythm. This was not 
possible to achieve for our multicentric population. However, changes in CTX remained statistically significant 
in accordance with the recent study by Briot et al.6 These authors confirm a major decrease in CTX levels in 
patients presenting SpA with a trend to an increase in bone formation, suggesting that anti-TNF therapy is 
associated with bowel and rheumatic inflammatory diseases, with a decrease in bone resorption and an 
improvement of bone formation. The mechanisms underlying this decrease in bone resorption remain to be 
clarified. Soluble receptor activator of NF-κB ligand (sRANKL) as well as its decoy receptor osteoprotegerin 
(OPG) are certainly relevant candidates for such modulation as sRANKL has been identified as a major mediator 
in bone resorption associated with chronic inflammation.' Furthermore, we recently showed an increased 
production of sRANKL and OPG by inflamed mucosa in CD.8 However, in a subgroup of our CD patients 
treated with infliximab (n = 30). we were unable to find a significant difference in sRANKL and OPG serum 
levels before and after treatment (2.9 ± 2.38 pg/mL and 2.87 ± 2.43 pg/mL for sRANKL. before and after 
treatment, respectively; paired t-test: P - 0.93· 1012.8 ± 456.7 pg/mL and  974.9 ± 492.6 pg/mL for OPG. before 
and after treatment, respectively; paired t-test: P = 0.51). In our hands, an uncoupling effect on bone metabolism 
was observed in six of 71 patients, it seems therefore that individual response might occur and further studies 
will be required in large population to determine the relationship between the type of response (i.e. bone 
formation and/or bone resorption) and CD. Finally, the mechanisms of bone metabolism improvement after 
infliximab in CD may be complex and possibly heterogeneous among patients, involving both changes in bone 
formation and resorption through a better control of local inflammation, intestinal mucosal healing and direct 
inhibition of TNF. 
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